Caetano et al. [67] demonstrated in KRAS mutant LUAD that IL6 inhibitors reduced autocrine growth and survival signaling on tumor cells, but also markedly altered the lung microenvironment to adopt an anti-tumor phenotype evidenced by reduced pro-tumor immune cells (M2-type macrophages, granulocytic myeloid-derived suppressor cells, and T-regulatory/Th17 cells) and increased anti-tumor Th1 and CD8+ T cells. The gene discussed is KRAS; the disease is neoplasm.